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Abstract 
 Renal transplantation has become the treatment of choice for patients with end-stage 
renal disease. Recognizable improvements in early graft survival and long-term graft function 
have made kidney transplantation a more cost-effective alternative to dialysis. Moreover, the 
discovery of new immunosuppressive agents has made a significant impact on short-term 
graft survival. 
 Despite these improvements a substantial portion of grafts develop progressive 
dysfunction and fail within a decade by a process known as chronic rejection. Ongoing 
monitoring of kidney transplants is crucial to avoid the development of this condition. The 
most common approaches to monitor renal allograft function are the measurement of the 
serum creatinine levels, whose variations are not specific for rejection and sometimes there 
is a need to perform renal biopsies, which is a risky process and only diagnoses rejection 
once it is installed. 
 The main objective of this study was to create an immunological and cellular profile 
associated with chronic dysfunction establishment that could serve as a diagnostic tool. For 
this purpose, a series of different analyses were carried out on 71 patients with 
stable/normal renal function after the transplant and the results compared to the same tests 
performed on 27 patients who have been diagnosed with chronic graft rejection.  
 The development of an antibody screening method in the urine of renal transplant 
patients was one of the most relevant points in the study with more than half the patients 
diagnosed with chronic rejection presenting anti-HLA Class I antibodies in urine. 
 The normalized gene expression values found in the urinary sediment of patients 
diagnosed with chronic rejection confirm the involvement of inflammation in the 
development of chronic rejection. Furthermore, the increased normalized gene expression 
levels for B cells markers (CD19 and CD79B) in chronic rejection group suggest the 
existence of B cells clusters that can function as a tertiary lymphoid tissue which can harbour 
B cell maturation into memory B cells and antibody producing plasma cells. 
 According to the receiving operating characteristic curves, CD19, CXCL10 and TNF3 
were the genes with the highest diagnostic values for chronic rejection.               
This study demonstrates that analysis of the urine of renal transplant patients could 
give valuable information that may allow the monitoring of the transplant without resort to 
invasive methods. Nevertheless, only the combination of results obtained in the urine and 
blood samples can provide a complete and accurate assessment of the allograft condition. 
Keywords: Renal transplant; Chronic rejection; Biomarkers. 
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Resumo 
 A transplantação renal tornou-se a terapia de eleição para doentes com insuficiência 
renal crónica terminal. As melhorias, em termos de sobrevivência do enxerto e da função 
renal a longo prazo, fizeram com que a transplantação renal tenha uma melhor relação 
custo/benefício do que a diálise. A acrescentar a isto, a introdução de novos agentes 
imunossupressores teve um impacto significativo na sobrevivência do enxerto a curto prazo. 
 Apesar destas melhorias, uma quantidade substancial dos enxertos desenvolvem uma 
disfunção progressiva com perda de função total no prazo de uma década, através de um 
processo denominado rejeição crónica. A monitorização funcional dos rins transplantados 
torna-se crucial para tentar evitar o desenvolvimento desta condição. Os métodos mais 
comuns para realizar a monitorização da função do enxerto são as medições dos níveis de 
creatinina no soro, sendo que estas variações não são específicas para a rejeição e ainda, por 
vezes, é necessário realizar biopsias renais, que é um processo arriscado e que só 
diagnostica esta rejeição depois de esta estar instalada. 
 O principal objetivo deste estudo foi desenvolver um perfil imunológico e celular, 
associado ao estabelecimento da disfunção crónica, que possa servir como ferramenta de 
diagnóstico. Tendo isto em vista, um conjunto de análises foram efetuadas em 71 
transplantados renais com uma função renal estável e os resultados, comparados com os 
mesmos testes efetuados em transplantados renais que tinham sido diagnosticados com 
rejeição crónica. 
 O desenvolvimento de um novo método de seleção de anticorpos na urina de 
transplantados renais foi um dos pontos mais importantes neste estudo, sendo que mais de 
metade dos transplantados com rejeição crónica apresentou anticorpos anti-HLA Classe I na 
urina. 
 Os valores da expressão génica normalizada encontrados para as células do 
sedimento urinário dos transplantados renais, confirmaram o envolvimento da inflamação no 
desenvolvimento da rejeição crónica. Além disso, os valores mais elevados de expressão 
génica normalizada para os marcadores da célula B (CD19 e CD79B), no grupo da rejeição 
crónica, sugerem a existência de aglomerados de células B que funcionam como um órgão 
linfoide terciário, capaz de albergar a maturação da célula B em células de memória e em 
células do plasma produtoras de anticorpos. 
 De acordo com a análise feita das curvas características de operação do recetor, os 
genes CD19, CXCL10 e TNF3 foram os que obtiveram maior valor de diagnóstico para a 
rejeição crónica.  
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 Este estudo comprova que a análise da urina de transplantados renais, no futuro 
breve, pode fornecer informações valiosas, permitindo assim, a monitorização funcional 
destes doentes sem recurso a procedimentos invasivos. No entanto, só a combinação dos 
resultados obtidos na urina e no sangue pode oferecer uma avaliação completa e precisa da 
condição do enxerto. 
Palavras-chave: Transplantação renal; Rejeição crónica; Biomarcadores.
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1.1 Transplantation 
The term transplantation, in immunology, refers to the act of transferring healthy 
cells, tissues or organs from one person (donor) to another (receptor/recipient) in order to 
re-establish a lost function. The organs, tissues or cells transplanted are called grafts (1, 2). 
  Organ transplant has revolutionized the treatment options for various diseases. 
Patients with end-stage renal disease (ESRD) only had dialysis as possible treatment. 
Nowadays kidney transplant has become the treatment of choice for most patients with this 
condition, mainly due to the better quality of life and increased survival that it offers when 
compared to dialysis (3, 4). 
The first fruitful experimental kidney transplants were performed at the Vienna 
Medical School in Austria with animals in 1902. Only in 1954, Joseph E. Murray and his 
colleagues at Peter Bent Brigham Hospital in Boston performed the first truly successful 
kidney transplant in humans from one twin to another identical twin. So we can consider 
transplantation as a recent phenomenon since the biggest developments have taken place 
within the past  60 years (5). 
Presently, there are two main barriers that need to be overcome in organ 
transplantation: first the disproportion between the number of patients waiting for the 
transplant and the number of organs available for transplant, the second and most important 
barrier is the immune system, as it recognizes the graft as foreign and initiates a series of 
mechanisms that lead to graft rejection (6, 7). 
Nowadays the methods available to monitor and evaluate graft function are the 
measurement of blood creatinine levels or invasive and painful procedures like biopsies. The 
main concerns with these methods are that variations on the creatinine levels are not 
specific of rejection and biopsies stand, as an expensive and difficult medical procedure that 
can lead to inaccurate diagnoses, since it only analyses a small piece of tissue that may not 
show any signs of rejection, when the rejection could be already installed on different 
regions of the graft. Furthermore, biopsies often detect pathological changes at advanced and  
irreversible stages of graft damage (8). 
Therefore, there is a need to develop more sensitive and specific methodologies 
based on donor and recipient genotyping, transcriptional and proteomic profile to 
differentiate and detect early stages of graft injury (9). 
The answer may well lie on the use of biomarkers in kidney transplants. Currently a 
biomarker is defined as  “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic responses 
Introduction  
 
3 
 
to a therapeutic intervention” by the Biomarker Definitions Working Group (10). Indeed, 
the validation of pre and post-transplant biomarkers can lead to better outcomes in graft 
survival as they can help understand the distinct molecular and cellular mechanisms triggered 
by allotransplants. The ideal biomarker should reflect alterations of allograft function as they 
happen, allow better matching between donor and recipient and get an insight of a person’s 
susceptibility to graft rejection (11). 
1.1.1 Transplant Types 
The origin of the graft determines the type of transplant. When the graft is 
transferred from one part of the body to another in the same individual it is called an 
autotransplant. When the graft is transferred between two genetically identical individuals 
from the same species is named isotransplant, this type of transplant is characteristic of 
transplants between twins. While a transplant concerning two individuals of the same species 
but genetically different is known as allotransplant. This is the most common type of 
transplant and the one studied in this work. At last, when a graft is transferred between 
individuals from different species is called xenotransplant (1, 2). 
Each type of transplant elicits a different immune response. For autologous and 
isotransplants the immune response is practically non-existent. In contrast, the xeno and 
allotransplants trigger a strong immune response due to the presence of cells from the 
donor that are recognized as foreign by the recipient’s immune system, that ultimately may 
lead to graft rejection. The different types of immune responses and the mechanisms 
involved in the process of graft rejection will be explained later. 
1.2 Graft rejection 
The process of rejection, in transplantation, is defined by the time post-transplant the 
rejection occurs and also, according to the histopathological characteristics presented by the 
graft on biopsies. There are 3 types of graft rejection: hyperacute rejection, acute rejection 
and chronic rejection. 
The hyperacute rejection occurs in the first 24 hours after transplant and it is 
characterized by thrombotic occlusion of the graft vasculature. Acute rejection usually 
happens on the first 6 months after transplant and the main feature is a rapid graft 
dysfunction due to inflammation, however, in the past three decades, there has been a 
dramatic reduction in the incidence of acute rejection with introduction of potent 
immunosuppressive drugs (1, 2).  
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Finally, chronic rejection is a result of a progressive functional decline of the graft 
over a period of months to years after transplant. Currently, chronic rejection is the most 
prevalent cause of late renal allograft loss and, as there is no cure for this condition, it is 
considered a major concern in the field (1, 2). The mechanisms and molecules involved in 
graft rejection will be described throughout the thesis.  
1.3 Major histocompatibility complex (MHC) 
The major histocompatibility complex (MHC), located on the short arm of 
Chromosome 6 (6p21), is a large region of DNA containing over 200 coding loci. In humans, 
the MHC is known as the “Human Leukocyte Antigen” system (HLA) and was first described 
in the 1950’s, when it was revealed that HLA antigens present on human leukocytes could 
react with antibodies produced during blood transfusions and pregnancies (12, 13) (Figure 
1). 
 At the present time, the involvement of these HLA molecules in the recognition and 
presentation of self and foreign antigens is well described (14). Moreover the HLA system is 
inherited as a HLA haplotype in a Mendelian fashion system, as you receive a haplotype from 
each parent, genetic recombination can lead to new allelic combinations (15). In clinical 
transplantation, they play a crucial role in the alloimmune response leading to graft 
acceptance or graft rejection (16). The new allelic combinations dramatically reduce the 
probability of two unrelated individuals to have identical HLA genes making the HLA the 
major immunological barrier for organ transplant as the number of HLA disparities between 
donor and receptor increases the risk of graft failure (14). 
The HLA system is divided into two regions encoding two different Classes of 
molecules, HLA Class I and HLA Class II. There is a third region between HLA Class I and 
Class II known as MHC III region that does not belong to the HLA system (17). 
The HLA Class I glycopeptide antigens are virtually expressed on the surface of most 
nucleated cells where they bind and present peptides to circulating CD8+ T cells, also 
known as cytotoxic T cells (Tc). The Class I region contains the classical HLA-A, HLA-B, and 
HLA-C genes that encode the heavy chains (α) of Class I molecules (18, 19). 
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Figure 1- Localization of the MHC complex on chromosome 6. The HLA system represents 
the most polymorphic genes of the human genome. The HLA genes are divided in HLA Class I and HLA Class II 
according to their structure, expression and function of the molecules they express. The structure of both 
Classes is also represented here. (Adapted from: AYALA GARCIA, M.A. [et al.]. - The major histocompatibility 
complex in transplantation. Journal of transplantation.2012 (2012) 842141.) 
The cell surface glycopeptide antigens of the HLA-DP, HLA-DQ and HLA-DR loci 
establish the Classic HLA Class II molecules and their function is to present peptides to T 
helper cells (Th). The expression of HLA Class II antigens is restricted to the antigen-
presenting cells (APCs), including dendritic cells (Dcs), B-lymphocytes, macrophages and 
endothelial cells (20), however they can also be expressed in other cells after stimulus. The 
products of the Class II genes DR, DP, and DQ, are heterodimers of two non-covalently 
associated glycosylated polypeptide chains; α and β, as shown in Figure I (7).  
The MHC Class III region of the genome encodes several molecules that take part in  
inflammation processes, including some complement components (21). 
The HLA Class I molecules display an elevated degree of polymorphism mainly due to 
the variable amino acid sequence of the α1 and α2 domains, which determine the antigenic 
specificities of the HLA Class I molecules .The polymorphisms of Class II molecules occur in 
the first amino terminal β1 domain of DRB1, DQB1, and DPB1 gene products. This 
polymorphism is essential to an  efficient adaptive immune response since it allows a large 
diversity of peptide antigen recognition and presentation to T cells (22).  
Conversely, the extremely high polymorphism contributes to the HLA disparities 
between donor and receptor emphasizing the importance of the HLA system in organ 
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transplant. There are a series of methodologies available to achieve donor receptor 
compatibility, including HLA Typing, Cross Matching and Antibody Screening (5). The  best 
match to a certain donor  is obtained by an algorithm defined by law in each country and is 
always changing mainly due to technological advances that help developing new ways to get 
closer to the perfect match but also due to ethics/moral concerns. 
1.4 The Immune System 
The immune system has the capacity to respond to external threats including 
microorganisms or peptides. This response can be divided into two types: innate response 
with a large spectrum of specificity or adaptive response with a restricted specificity. These 
two types of response are different but present a close collaboration between them to 
enhance the efficiency of the immune response (23).  
The first non-specific line of defence is provided by the innate immune system which 
includes the epithelial barrier, phagocytic cells such as neutrophils and macrophages, 
dendritic cells that capture and present antigens, cells that release inflammatory mediators 
such as mast cells and natural killer cells (NK) (24). The molecules that participate in the 
innate immune response are cytokines and plasma proteins such as complement factors and 
acute phase proteins (25). The innate immune response stimulates the adaptive immune 
response creating an important cooperation that makes the immune system able to respond 
to almost any type of aggression (25).  
Adaptive immune responses are initiated when antigen-receptors on lymphocytes 
recognize a foreign antigen. T-lymphocytes mediate cellular immunity and B-lymphocytes 
mediate humoral or antibody-mediated immunity. The adaptive immune system has an 
immunological memory, making the immune response faster and stronger  to the same 
antigen (26).  
1.4.1 T cell activation 
Alloantigens refer to the antigens expressed exclusively by the donor. These 
alloantigens are considered the main cause for graft rejection and the HLA allogeneic 
molecules stand as the major target for immune response due to their extremely high 
polymorphism associated with their extraordinary capacity to generate polyclonal T-cell 
responses.  
  As described before one of the functions of the HLA molecules expressed on the 
surface of the APC is to bind and present antigens to the T cells (27). These antigens are 
recognized by the T cell receptors (TCR) expressed on the surface of T cells. This is the first 
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step to initiate an immune response (28). The TCR consists of one α-chain and one β-chain 
that together directly recognize peptide-HLA ligands and, it is associated with CD3 subunits 
(29). Depending on the antigen, the HLA Class that binds the allogeneic peptide will differ as 
well as the core receptor on the T cell. The core receptor CD8 will help recognize HLA 
Class I molecules bound to the allogeneic peptide and CD4 will assist in the recognition of 
the peptide bound to the HLA Class II molecule (30). 
 The recognition of the peptide-HLA molecule is the first signal to initiate an immune 
response but alone is not enough to completely activate T cells. Two more signals are 
necessary to promote T-cell proliferation: cytokine secretion and effector function after T 
cell activation (18). 
The second signal can be costimulatory or coinhibitory and a variety of molecules can 
be receptors for this signal (31). The strongest receptor of costimulatory signals is CD28 
that is expressed on T cells (CD4 and CD8) and has two known ligands: CD80 and CD86. 
These ligands are expressed on activated APCs. The most common coinhibitory signal 
receptor is cytotoxic T-lymphocyte-associated protein 4 (CTLA4) that also can bind to 
CD80 and CD86 as it presents a similar structure as CD28 (32). However, when CTLA4 
binds to the APCs, sends an inhibitory signal that ends the immune response. Another 
molecule that has a crucial role in the immune response is CD40 ligand (CD40L) expressed 
on activated T cells. The CD40L binds to CD40, expressed on APCs, inducing the 
expression of CD80 and CD86, improving the efficacy of T cell activation (33). 
A third signal is required to complete the activation of T cells. Recent studies have 
shown that interleukin 12 (IL12) and interferon (IFN) α/β are the most important sources 
for this signal in various responses. There have also been some reports suggesting that 
IL1can provide a third signal, especially for CD4 T cells (34). 
All the mechanisms involved in T cell activation are schematized on Figure 2. 
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Figure 2- The three signals required for the stimulation of antigen-specific T cell. First, 
antigenic proteins go through antigen processing and then the peptides are presented through MHC Class I or 
II molecules for CD8 and CD4 T cells, respectively. The second signal is known as co-stimulation and is 
provided by molecules from B7 family member proteins CD86 and CD80 expressed on APCs. These B7 
proteins interact with their receptors such as CD28 present on T cells. Inflammatory cytokines such as IFN-
α/β, IL12, and IL1 constitute the third signal. (Source: Gujar SA, Lee PW. Oncolytic virus-mediated reversal of 
impaired tumor antigen presentation. Frontiers in oncology. 2014;4:77) 
1.4.2 Direct and Indirect allorecognition pathway 
Alloreactive T cells recognise alloantigens via two distinct, but not mutually exclusive 
pathways: direct and indirect (35). Direct recognition occurs when recipient T cells 
recognise intact donor MHC molecules complexed with peptide on donor APCs, without 
processing by recipient APCs. This happens, essentially because the majority of the grafts 
contain resident APCs like macrophages and dendritic cells (36). Allorecognition via the 
indirect pathway requires that recipient APCs migrate to the graft and process the donor-
HLA antigen before presenting it to recipient T cells. Both pathways contribute to allograft 
rejection (36).  
The direct pathway has been associated with acute rejection and the indirect pathway 
appears to have a bigger involvement in chronic rejection (37). A third pathway, which may 
serve as a link between the direct and indirect pathways, has been proposed. Recipient 
Dendritic cells can acquire intact HLA molecules from donor cells or tissues and at the same 
time have the capacity to activate recipient T cells leading to direct anti-donor alloimmune 
responses (Figure 3)(38). 
The indirect pathway activates naïve CD4+ (T-helper cells) as the foreign antigen is 
presented by a HLA Class II molecule. The direct pathway can activate both naïve T-helper 
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cells and naïve CD8+ cells depending on the HLA Class that presents the allogeneic peptide 
(25). 
 
 
 
 
 
 
 
 
 
Figure 3- The three pathways of allorecognition by T cells. In direct allorecognition, as the 
name suggests, T cells are activated directly by APCs or any cell expressing allogeneic MHC. The occurrence of 
indirect recognition relies on foreign antigen processing by autologous APCs. Then, peptides derived from 
these allogeneic antigens are cross-presented by autologous MHC Class II on autologous APCs. In semidirect 
allorecognition, allogeneic MHC Class I or MHC Class II molecules are assimilated and MHC-peptide 
complexes presented by autologous APCs. (Adapted from: ZAKRZEWSKI, J.L.[et al.]. - Overcoming 
immunological barriers in regenerative medicine. Nature biotechnology.32 (2014) 786-794.)  
Naïve CD8+ T cells differentiate into CD8+ cytotoxic T cells (CTLs) after foreign 
peptide–HLA Class I presentation, causing the release of cytokines, mostly IL12. The CTLs 
are effector cells of the immune system and their activation leads to the formation of 
granules that contain perforin and granzyme B (39). These molecules are released on the 
synaptic cleft between the effector cell and the target cell (39).  
Recent studies proved that perforin is the key molecule, since it forms transient 
pores on the surface of target cells, providing a short window of time for direct entry of 
granzyme B into the cytosol (40, 41). Once inside the target cell, granzyme B activates cell-
death pathways that operate through the activation of caspases (particularly caspase-3), but 
it also leads to cell death in the absence of activated caspases, by engaging aggregation of 
target cell death receptors, like Fas, by their cognate ligands, such as Fas ligand (FasL), on the 
killer-cell membrane, which results in classical caspase-dependent apoptosis (Figure 4) (35, 
42).  
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Figure 4- The granzyme B–Perforin cytotoxic pathway. Granzyme B and perforin are released 
from the granules of a cytotoxic cell to the synaptic cleft. Then perforin forms transient pores allowing 
granzyme B to enter the target cell. Once inside the target cell cytoplasm, granzyme B can initiate apoptosis 
through both caspase-dependant and caspase-independent pathways by cleaving a number of substrates. 
(Adapted from: HIEBERT, P.R., GRANVILLE, D.J. - granzyme B in injury, inflammation, and repair. Trends in 
molecular medicine.18 (2012) 732-741.) 
The naïve T-helper cells (nTh) are one of the first immune cells to be activated post-
transplant, playing a key role in rejection. When activated the nTh cells have the capacity to 
differentiate into one of several T helper cell lineages, including the classical T-helper 1 (Th1) 
and T-helper 2 (Th2), T-helper 17 (Th17) and regulatory T cells (Treg), each with a 
characteristic cytokine profile, transcription factor, and signalling pathway through which 
their differentiation is mediated (Figure 5) (43). 
The presentation of the antigen to naïve CD4+ T cells with the presence of IL12 and 
NK cell-derived interferon gamma (IFNγ) induces Th1 cells activation (44). This activation 
requires T-bet (T-box expressed in T cells) and signal transducer and activator of 
transcription 4 (STAT4) (45). When activated, they predominantly produce IL2, IFNγ and 
tumour necrosis factor α (TNFα).Th1 cytokines collectively promote cell-mediated immune 
responses (46).  
Th2 activation is stimulated by IL4 and IL33 and depends on GATA3 and STAT6 as 
transcription factors (47). Cytokines produced by Th2 activated cells include IL4, IL5, IL6, 
IL9, IL10 and IL13 (48). Some of these Th2 cytokines downregulate Th1 cytokines 
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productions, while others, in conjunction with interleukins released from tissue-derived and 
dendritic cells (IL25, IL31, IL33), facilitate humoral responses (49-51).  
Th17 cells are involved in humoral immune responses, but may also contribute to the 
cell-mediated immune responses due to their ability to produce interleukin-17 (IL17). Th17 
polarization in humans is dependent upon IL1b, IL6, IL21, and IL23 and the transcription 
factor, RORγt (52). Once activated, Th17 cells secrete IL17A, IL26 and IL22 that stand as 
potent pro-inflammatory mediators. Furthermore, the release of these cytokines causes 
chemokine secretion by resident cells stimulating the recruitment of neutrophils and 
macrophages to inflammation sites (53).  
The activation of macrophages by Th1 and some Th17 cells will trigger cell-mediated 
immune responses. The macrophages are remarkable phagocytic cells with huge plasticity, so 
naturally, they are considered one of the most important immune effector cells (54). 
Th2 and Th17 cells activate B cells that mature into plasma cells that are known by 
their ability to produce antibodies against the foreign antigens. These antibodies are called 
immunoglobulins (Ig) and they can be divided into five classes, each of which mediates a 
characteristic biological response following antigen binding (46). 
Regulatory T cells are a heterogeneous group of T lymphocytes that control 
potentially harmful autoreactive T cells in the periphery. In transplantation, they seem to be 
involved in the establishment of tolerance (55). Their development is dependent on the 
expression of the transcription factor forkhead box p3 (FOXP3). IL2 and CD25 also seem to 
have an important part in the development of natural Treg cells. The induction of Treg cells 
is favoured by environments where transforming growth factor (TGF)-β1 is present. 
Thymus-derived Tregs suppress alloreactive Th1 and Th2 cells as well as alloreactive CD8+ 
Tcells and alloantibody-producing B cells by secreting immunosuppressive cytokines including 
TGF-β1, IL10 and IL35. This ability is crucial to maintain immune homeostasis (51).  
It should be noted that, more than describe all the mechanims of the  immune system 
in detail, this introduction was intended to show the key agents involved in immunological 
responses as well as their immunological diversity and above all, ilustrate the 
cooperativeness of the different types of immune responses responsible for graft rejection. 
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Figure 5 - CD4+ T helper cell differentiation and CD8+ T-cell cytotoxicity. HLA Class I 
molecules induce  CD8+ T-cell cytotoxicity whereas HLA Class II APCs conduct the differentiation of naive 
CD4+ T cells towards T helper (Th) 1, Th2, Th17 cells or regulatory T cells depending on the cytokine balance 
in the local microenvironment. The different Th cell subsets and Treg cells have different characteristic 
cytokine profiles, transcription factors necessity and signalling pathways.  
(Withdrawn from: BRUSSELLE, G.G. [et al.] - New insights into the immunology of chronic obstructive 
pulmonary disease. Lancet.378 (2011) 1015-1026.) 
1.5 B cells and their role in transplanted organ rejection 
As explained before, the main role of B-cells is to serve as precursors of antibodies. 
The activation of B-cells takes place when the antigen binds to the B-cell receptor (BCR) 
that generates a signalling process that culminates in presentation to CD4+ cells of the 
antigen and BCR by the HLA Class II molecules, as described above. In this interaction there 
is another subtype of T-cells that is essential to B cell maturing: T follicular helper cells (Tfh). 
These Tfh deliver the cytokines necessary, predominantly IL21 (56, 57). This creates the 
proper environment to B cells to differentiate into two cells types: memory B cells and 
antibody-producing plasma cells.   
The antibodies produced by these plasma cells are specific for the donor cells, 
increasing the immune response against the graft cells and lowering the graft survival (58). 
This the primary role of B cells in transplant rejection. Still, a considerable number (30%–
50%) of kidney and heart allograft recipients undergoing chronic rejection do not seem to 
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have detectable circulating HLA antibodies or complement deposits in the graft. Moreover 
some recent studies have shown that B cells may also contribute to transplant rejection, 
perhaps by facilitating cellular immune responses (59).  
In addition to producing antibodies, B cells influence T cell responses by mechanisms 
such as antigen presentation, cytokine production and costimulation for productive immunity 
(59).  
Memory B cells contribute to serological immunity by rapidly differentiating into 
plasma cells when exposed to the same antigen as when they were formed. CD27 is the 
known marker of memory B cells (60, 61).  
In contrast, a specific subset of B cells, regulatory B cells (Breg), seem to have the 
ability to induce tolerance by either blocking the antigen recognition or by suppressing 
immunity by secreting IL10 (55, 62).  
1.6 Hyperacute Rejection 
Hyperacute rejection is humorally mediated and happens due to the existence of 
preformed donor-specific anti-HLA antibodies. These antibodies bind to blood vessels and 
activate the complement system, which initiates a cascade of events leading to coagulation of 
platelets and immediate circulation blockage that ultimately results in loss of graft function 
(63, 64). These preformed anti-HLA antibodies can be induced by prior blood transfusions, 
multiple pregnancies or even previous transplants (12, 13, 65).  
1.7 Acute Rejection 
1.7.1 Cell-mediated Immune response in acute rejection 
A sudden increase in serum creatinine, fluid retention, and occasionally fever and 
graft inflammation are the symptoms that patients with acute cellular rejection often exhibit.  
Since the current therapy is mostly directed at T cells, the incidence of acute 
rejection is approximately 5%–10% in the first year in unsensitized patients (66). Clinically, 
acute cellular rejection is characterized by the gathering of mononuclear cells in the 
interstitium associated with inflammation of the tubules and, occasionally, of the arteries 
(63).  
The mononuclear cells that infiltrate the interstitial space around tubules are 
essentially CD4+ and CD8+ T cells (67). T cells contain cytotoxic granules (perforin and 
granzyme A and B) or the cytotoxic effector ligand, FasL that are able to trigger apoptosis by 
the mechanisms described above. This is naturally accompanied by an increase in the CTL 
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associated transcripts mRNA: granzyme B, perforin, and FasL, as well as T-bet (68-70). 
There are other cytokines and chemokines selectively expressed in acute rejection like IFNγ, 
TNFβ, TNFα and chemokine (C-C motif) ligand 5 (CCL5) (71).  
Another important feature of acute rejection is the invasion of the tubular epithelium 
by infiltrating T cells and macrophages, clinically known as tubulitis (63). In severe cases, graft 
dysfunction and progressive tubular loss can occur due to rupture of the tubular basement 
membrane causing the release of proteins into the interstitium (72). The degree of apoptosis 
correlates with the number of cytotoxic cells and macrophages recruited to the tubular 
epithelium (72).  
There are other molecules present in tubular epithelium like CD103 and Tregs (73). 
CD 103 seems to play a role in fixating T cells in the epithelial layer by binding to E-cadherin. 
Until now, the function of Tregs in the tubules is not clear yet. It is only natural that the 
levels of mRNA for CD103, perforin, granzyme B, and FOXP3 are increased in the urine of 
patients with acute rejection (74).   
During acute rejection, a variety of chemokines are produced in the graft, including 
C-X-C motif chemokine 10 (CXCL10), CCL2, CCL3, CCL4, CCL5, and XCL1  that are 
postulated to participate in T cell recruitment to the graft and cytokines TNFα, TGF-β1, and 
IL6 (75-78).  
TGF-β1 is the central molecule that regulates epithelial-mesenchymal transition and 
its expression by tubular cells, leads to abnormal phenotypes usually seen in grafts suffering 
from rejection (79). 
Infiltrating cells express several chemokine receptors, including CCR2, CCR5, 
CXCR3, and CX3CR1. The pattern of expression suggests a predominance of Th1 over Th2 
cells (75). CCR5 is probably important in the pathogenesis of rejection, as humans who are 
homozygous for inactive 32 forms have a greater graft survival than those with the active 
form (80).  
Glomerulitis is, sporadically, a visible feature of acute cellular rejection. The cells in 
the glomeruli are fundamentally a mixture between CD3 T cells and a small number of 
CD68 macrophages (81). The mechanisms proposed for cell mediated injury to the graft are 
schematized on Figure 6. 
1.7.2 Humoral Immunity in Acute rejection 
Approximately 25% of acute rejection episodes are due, at least in part, to anti-HLA 
antibodies against the donor. Risk factors include presensitization and reduced 
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immunosuppression (82). However, despite the immunosuppression treatment chosen, 
there is a possibility to develop an acute humoral rejection (AHR), even with strong 
depleting T cell therapy (78).  
The binding of anti-donor antibodies to the endothelium of the graft activates 
complement, which triggers the recruitment of cellular infiltrates, neutrophils and 
macrophages in the capillaries (83). Both cellular and antibody-mediated acute rejection 
episodes are more frequent in sensitized patients than in patients without circulating 
antibodies (84).  
 
 
 
 
Figure 6 – Proposed mechanisms of cell-mediated graft injury. Cytokines released by 
inflammatory cells (IL17 and TNFα) induce the release of chemokines (CCL2, CCL5, CX3CL1) that recruit T 
cells to the graft. These recruited T cells, in particular cytotoxic T lymphocytes are thought to promote 
apoptosis either by granzime-perforin pathway or by the engagement of Fas by FasL on activated T cells. T cells 
are kept on the tubular epithelium by CD103 binding to E-cadherin. The production of TNFβ by the tubules 
stimulates FOXP3 and IL15 expression. IL15 has the ability to inhibit perforin production. Epithelial-
mesenchymal transition is a phenotype seen in various grafts suffering from acute rejection and results from the 
exposure of tubular cells to TGFβ, which is a crucial protein in regulation of this transition. (Withdrawn from: 
CORNELL, L.D. [et al.]. - Kidney transplantation: mechanisms of rejection and acceptance. Annual review of 
pathology.3 (2008) 189-220) 
1.8 Chronic Rejection 
Chronic rejection is characterized by a fairly slow, but unpredictable rate of decay in 
renal function after the initial 3 months post-transplant (85). 
Grafts suffering from chronic rejection exhibit many features seen in healing wounds, 
including fibroblast, endothelial cell, or epithelial cell proliferation and collagen deposition 
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within the graft parenchyma and blood vessels; all of these processes result in interstitial 
fibrosis, ischemia, and the loss of graft function (86, 87). Other histopathological 
characteristics of chronic rejection are fibrous intimal thickening of the arteries, 
glomerulosclerosis and tubular atrophy. These symptoms are often found in combination 
with an increase in creatinine levels and also with aggravation of hypertension (85, 88).  
Through the years some risk factors of chronic rejection have been identified, where 
the most relevant is the existence of previous acute rejection episodes as the half-life of 
cadaveric allografts decrease in patients who had episodes of acute rejection (89).  
The timing of the acute rejection episodes also influence the outcome of the graft, as 
the episodes of acute rejection that take place within the first 3 months after transplant have 
a lower impact on chronic rejection comparing  with the ones occurring after 3 months 
transplant (90). 
Detection of anti-HLA antibodies, both before and after transplant, is associated with 
chronic allograft rejection. The requirement of dialysis during the first week after 
transplantation, known as delayed graft function, is also consider a risk factor of chronic 
rejection (58). Finally, the recipient age and race may also have an effect on the development 
of chronic rejection (91, 92). 
The majority of risk factors identified are related to recognition of foreign antigens 
on the graft by the recipient, which triggers cellular and humoral responses, as explained 
above. In chronic rejection, the humoral immunity appear to have the biggest role, but both 
types of immune responses are responsible for graft rejection (86). 
Nowadays the complement component 4d (C4d) deposits have been taking attention 
as in situ marker for humoral rejection. C4d is one of the degradation products of 
complement component C4, that remains covalently linked to the tissue after activation. In 
renal allograft biopsies with chronic rejection C4d deposits have been found in the 
peritubular capillaries in 34% of late allograft biopsies (93).  
Another aspect that confirms the impact of humoral responses in chronic rejection is 
the presence of antibodies in circulation. These antibodies can be against HLA or non-HLA 
antigens. Renal transplant recipients with anti-HLA antibodies are, in theory, 5–6 times more 
likely to develop chronic rejection and, eventually, lose their grafts (94). Still, there are a 
large number of acute and chronic rejection episodes that occur in the absence of circulating 
anti-HLA antibodies. This is consistent with the data of recent studies suggesting that the 
antibodies found in circulation might not reflect what really is being produced locally in the 
graft (95).  
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There is some data reporting non-specific antibodies binding to endothelial cells in 
renal transplant recipients, suggesting the involvement of antibodies against non-HLA 
antigens in chronic rejection (96). 
In conclusion, chronic rejection is the term used to describe the long-term loss of 
function in transplanted organs as consequence of an accumulation of different injuries to the 
graft, befalling in both early and post-transplant period. Nevertheless, the mechanisms 
behind chronic rejection are far from clear and more comprehensive studies covering the 
pathogenesis are obligatory (97). 
1.9 Tolerance in Transplantation 
1.9.1 The concept of tolerance in Transplantation 
There are two ways to define tolerance in human transplantation: clinical and 
immune tolerance. The term clinical tolerance refers to the survival of the graft  in the 
absence of non-specific immunosuppression agents (98). On the other hand, immune 
tolerance is related to the absence of a visible immune response against the graft without 
non-specific immunosuppression agents (99). Evidently, the achievement of tolerance is the 
ultimate goal in transplantation and it is an area of intensive study with numerous tolerogenic 
protocols being  attempted in humans, but the majority has failed to accomplish the 
desirable effect (100).  
The alloimmune response can be separated into central and peripheral tolerance, 
according to the mechanisms that induce a tolerance state. These are related and not 
mutually exclusive (101). 
Central tolerance consists on the removal of T and B autoreactive lymphocytes by a 
process known as clonal deletion. T and B cells mature in the thymus and in the bone 
marrow, respectively (102-104). 
In some cases, T or B cells with self-reactivity escape from the thymus or bone 
marrow and numerous mechanisms take action to try to control or eliminate these cells. 
These mechanisms constitute the Peripheral tolerance, including deletion and apoptosis, 
anergy and regulation or suppression (105). 
The deletion mechanism of self-reactive T lymphocytes, in both thymus and 
periphery, is achieved through apoptotic cell death. Fas (CD95) with its ligand (Fas-L or 
CD95L) mediate this process on T cells, and can occur in developing thymocytes as well as 
in mature T cells (106). 
Introduction  
 
18 
 
Anergy is a state of immune unresponsiveness of T or B cells to further antigenic 
stimulation as a consequence of absent costimulation (107, 108).  
Lastly, the third mechanism of peripheral tolerance is called regulation or suppression 
of the immune response where the most important cells known, until now, are the 
regulatory T cells. These cells control the immune response to foreign antigen to make sure 
the host remains unharmed (109). The hallmark of Treg cells is the transcription factor 
FOXP3, who controls the molecular programs involved in mediating Treg function (110). 
Nonetheless, the mechanisms by which Treg cells exert their effects are not completely 
understood (111). 
In recent years, an interaction between Tregs and regulatory B cells (Bregs) has been 
discovered and it has been suggested that these subtypes collaborate to promote tolerance 
in organ transplants. Lee et al. (112) established that adoptively transferred Bregs require the 
presence of Tregs to maintain tolerance, and that adoptive transfer of Bregs increases the 
number of Tregs. They had previously demonstrated the ability of Bregs to transfer 
tolerance to untreated, transplanted animals and also that Bregs are antigen specific. As a 
final point, they suggest TGF-β1 as the possible intermediate to Bregs promoting Treg 
activation, supporting graft survival (112.  
1.9.2 Accommodation 
Accommodation refers to acquired resistance of an organ or tissue to immune-
mediated injury. Accommodation can also be defined as a condition in which an allograft has 
a normal function, despite the presence of antibodies in the recipient specific against the 
graft (113, 114).  
The first time that accommodation was observed was in AB0-incompatible renal 
transplants, which were surprisingly functional and able to subsist after anti-blood group -A 
or –B antibodies were momentarily removed from circulation of graft recipients (115, 116). 
There were proposed 3 mechanisms by which accommodation could be achieved: a 
change in antigen so that less antibody would bind, modification of antibodies so that they 
would be less cytotoxic or an adjustment in the graft so that it became resistant to  humoral 
immunity (117). After some studies, the hypothesis with more supporting evidence was the 
one proposing that the graft could become unaffected by the antibodies against it. The major 
proof of this theory is C4d deposition found in biopsies without other signs or symptoms of 
rejection. Complement fixation, advocates that antibody binding is intact in accommodated 
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organs, but at the same time the absence of lysis suggests that some form of regulatory 
pathway is the basis for graft survival in accommodation (118).  
Accommodation can be considered as a positive response to transplantation as it 
prevents acute types of humoral injury. Conversely, by preventing acute injury, 
accommodation allows chronic processes to develop, producing damage to the graft (119). 
There is the possibility that the same proteins and pathways responsible for preventing initial 
harm to the graft might be the ones causing the impairment later in time (114). 
The prevalence of accommodation after renal transplantation maintain as the 
fundamental question awaiting answer. Developments in the management of patients with 
antibodies against AB0 and HLA antigens, will possibly bring progress in the understanding of 
how frequent is accommodation and what consequences it carries. Clinical studies may also 
provide hints concerning manipulations that permit or even induce accommodation (114).  
1.9.3 Immunosuppression in transplantation  
The objective of immunosuppression is to prevent or treat allograft rejection and at 
the same time minimize drug toxicity responsible for infection and malignancy (120).  
Combinations of several agents are used concurrently and in different 
immunosuppressive regimens that can be classified as induction, maintenance, or anti-
rejection regimens. Induction regimens provide intense early post-operative immune 
suppression, while maintenance regimens are used throughout the patient's life to prevent 
both acute and chronic rejection (120). Induction immunosuppressive agents consist of 
depleting and non-depleting protein drugs (polyclonal and monoclonal antibodies) and 
maintenance immunosuppressive therapies include small molecule drugs with two central 
categories: calcineurin inhibitors and antiproliferatives (120).  
Calcineurin inhibitors suppress the immune system by preventing IL2 production in T 
cells. The most commonly used and better described calcineurin inhibitors are Cyclosporine 
and Tacrolimus. The main side effects of these agents are hypertension, nephrotoxicity, 
neurotoxicity, and lipid abnormalities giving rise to an increased risk of death from 
cardiovascular complications (121). The antiproliferatives more frequently applied are 
Sirolimus and Everolimus and they exert their function by inhibiting IL2 and IL15 driven 
proliferation of B and T cells and also vascular smooth muscle cells (122). Furthermore 
Sirolimus seem to have the ability to decrease antibody production by B cells. The most 
common side effects are hyperlipidaemia, cytopenias and dyslipidaemia (123). 
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The main challenge with  immunosuppression strategies is to get the right balance 
between the immunosuppressive action that avoid  rejection episodes and the drug toxicity 
that leads to undesirable side-effects as explained above. The ideal immunosuppressive 
strategy would ideally be the one that stimulates the development of tolerance to 
alloantigens and at the same time promotes successful withdrawn of  immunosuppression 
(124). 
1.10  Biomarkers in Renal Transplantation 
Efficient application of biomarker identification can allow personalized therapy for renal 
transplant patients, since it might permit early detection and identification of renal graft 
status, guide clinicians in minimizing the risk of graft rejection events and offer vital 
information concerning withdrawal of immunosuppression (125, 126).  
Needle biopsy still is the most common diagnostic tool to detect rejection of renal 
allografts. As previously mentioned, it is an invasive procedure that is always subjected to a 
certain percentage of error and even the interpretation of the results can vary between 
pathologists (127, 128). 
Nucleic acid-based assays (principally micro-array assays and quantitative PCR (qPCR), 
proteomics and metabolomics-based approaches represent alternatives for the development 
of biomarkers of allograft status (124). 
Through the years various studies regarding biomarkers of rejection (acute and chronic) 
have been executed. Sarwal et al. (129) revealed extensive differences in gene expression 
profiles of RNA isolated from 67 biopsy specimens. They suggested that the variances in 
gene profile were associated with differences in immunologic and cellular features and 
clinical course (130).  
Furthermore, in a report from Desvaux et al. (69) 43 human renal-allograft biopsies 
were quantified for mRNA expression of granzyme B, Fas ligand (FasL), IFN-γ, IL4 and IL6 
with a qPCR method. They concluded that upregulated granzyme B and FasL mRNA 
expression was correlated with all allograft rejection types (p < 0.01).  
Another important work done on biopsies of kidney transplant patients was the one 
done by Oliver Thaunat et al. (95) where it is stated that the inflammatory infiltrate, present 
in chronic rejection, becomes organized into an ectopic lymphoid tissue, which harbors the 
maturation of B cell clusters responsible for humoral responses against the graft. Additionally 
they suggested that this maturation could be impeded by blocking certain genes (95). 
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The chance to measure gene-expression profiles in the peripheral blood and/or urine 
from kidney transplant patients allows the testing of numerous hypotheses by non-evasive 
methods and will have a direct impact on clinical practice. In a small study of 25 transplant 
recipients, granzyme B, Fas ligand (FasL) and perforin mRNA were significantly elevated in 
peripheral blood and graft tissue from patients with acute rejection, compared with their 
levels in allografts without rejection (131).  
Conversely, the multicentre Clinical Trials in Organ Transplantation (CTOT) -04 study 
was designed to detect a urinary-cell mRNA signature from a panel of nine candidate genes 
identified in previous studies. granzyme B and perforin were both included in the nine 
candidate genes in the study, but the best-fit model did not include these genes. Moreover, 
this study showed that a signature derived from CD3E mRNA, CXCL10 mRNA and 18S 
ribosomal RNA could discriminate between biopsy samples showing acute rejection versus 
those that had no rejection (132). CXCL10 together with CXCL9 are IFNγ-dependent 
chemokines and they are critical regulators of leucocyte trafficking and activation which are 
dynamically expressed in multiple transplant scenarios (133). 
 Multiple studies have shown an association between these chemokines and allograft 
injury (134, 135). This association was a confirmed on a previous work done in our lab 
where CXCL10, CXCL9 and TGF-β1 were selected as decent biomarkers for chronic 
rejection by the analysis of the receiving operating characteristic (ROC) curves (data not 
published).  
1.11 Objectives 
Chronic rejection is currently the most prevalent cause for kidney allograft failure 
and the mechanisms involved in this condition are far from clear. So the need to determine a 
genetic, genomic and humoral profile associated with chronic rejection, in kidney transplant 
patients, is evident. 
In order to assess this profile, the following specific objectives were delineated: 
- Evaluate the impact HLA mismatches in graft function and in humoral responses; 
- Perform the screening of anti-HLA antibodies in both urine and blood samples; 
- Establish a genomic profile of immune response mediators, related to chronic rejection, in 
the urine of renal transplant patients; 
- Assess the predicting value of the genetic, genomic and humoral changes in the 
establishment of chronic rejection. 
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2.1 Population in study 
The urine and blood samples necessary for this work were collected from patients 
submitted to renal transplant for more than two years, under regular clinical consultation on 
the Renal Transplant Unity from the “Centro Hospitalar Universitário de Coimbra” E.P.E. 
 The patients in this study can be divided into two groups: one with patients with a 
stable renal function and other with patients who have been diagnosed with chronic 
dysfunction. The demographic features that allowed the samples distribution to each group 
are displayed on Table I.  The most relevant clinical events of both groups are exhibited on 
Table II. A total of 99 samples were gathered thanks to the collaboration of Pathology Unit.  
It was also included a control group consisting of 9 healthy individuals. 
Table I – Demographic features of both group of patients present in the study. 
 
Legend: M - male; F - Female; BMI - Body mass index; CsA -  Cyclosporin A; FK506 - Tacrolimus;  
PRA - Panel Reactive Antibody; mg - milligrams; Kg - Kilograms; SD - Standard Deviation. 
 
 
 
 
 
 
 
 
Group NF 
N=72 
(Normal 
Function) 
 
Group CR 
N=27 
(Chronic 
Rejection) 
Sex (M/F) 42/30 20/7 
 
Age 
(Years; Mean ± SD) 
55,79 ± 11,37 49,04 ± 12,92 
 
BMI 
(Mean ± SD) 
26,42 ± 3,904 24,33 ± 4,768 
Organ Source Cadaveric Cadaveric 
PRA (%) 
 
[0-20%]-95,84 
 
[21-50%]-4,16 
 
[0-20%]-96,3 
 
[21-50%]-3,70 
 
Immunosuppression CsA/ FK506 
(mg/Kg) 
 
CsA - 0,15 
 
FK506 – 8 
 
CsA - 0,15 
 
FK506 - 8 
 
Time post-transplant 
(Years; Mean ± SD) 
9,43 ± 5,71 11,8 ± 5,60 
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Table II – Most relevant clinical events of both groups. 
 Group 1 N=73 
(Normal Function) 
Group 2 N=27 
(Chronic rejection) 
Original disease (%) 
 
PKD-13.89 
CGN-15.27 
CP-6.94 
Undetermined-63.90 
 
PKD-11.11 
CGN-7.40 
CP-11.11 
Undetermined-70.38 
 
Creatinine Levels 
(mg/ dl; Mean ±SD) 
 
1,17 ±  0,26 
 
2,71 ± 1,16 
 
Acute rejection episode 
within the first month after 
transplant (%) 
 
 
 
5.56 
 
 
11.1 
 
Cold ischemia 
(hours; Mean) 
 
 
19 
 
 
18 
 
Diabetes after transplant (%) 
 
 
16.7 
 
 
14.81 
 
Infections- Positivity for CMVab (%) 
 
 
95.83 
 
 
92.60 
 
Legend: PKD - Polycystic Kidney Disease; CGN - Chronic Glomerulonephritis; CP - Chronic 
Pyelonephritis;  CMVab - Cytomegalovirus antibody; SD - Standard Deviation. 
2.2 Processing peripheral blood samples 
2.2.1 DNA extraction 
The blood samples were collected to vacuette® blood collection tubes. Then 200 μL 
of each sample were withdrawn to proceed to the DNA extraction according to 
MagAttract® DNA Blood Midi M48 kit (Qiagen®) protocol. 
This protocol is based on the DNA binding to magnetic particles coated with silica in 
the presence of a chaotropic agent. The process begins with the addition of ML buffer 
resulting in cell lysis, then MagAttract B (solution that contains the magnetic particles in 
suspension) is added and the DNA binds to the magnetic particles. The isolation of the DNA 
is achieved due to the presence of a magnet that allows the magnetic particles with DNA to 
be isolated. 
  There were some washing steps during this method and in the final step the DNA 
was eluted in 300 μL of Tris- Ethylenediaminetetraacetic Acid (TE). The tubes containing the 
DNA of each sample were stored at 4ºC. 
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2.2.2 Blood serum isolation  
The blood was collected to vacuette® blood collection tubes that were submitted to 
1465 RCF centrifugation during 8 minutes (Kubota 5910) allowing serum separation from 
the other blood components. The serum was collected into 1,5 mL Eppendorf tubes and 
stored at 4ºC. 
2.3 Processing urine samples  
There were collected about 15 mL of urine into vacuette® urine collection tubes.  
The tubes were centrifuged during 25 min at 1465 RCF. The supernatant was transferred 
into 2mL Eppendorf for antibody screening and stored them at -25ºC. The pellet (urinary 
sediment) was resuspended in 1 ml of Phosphate Buffer Saline (PBS) 1x and 100 μL were 
transferred to a 1,5 mL Eppendorf tube for DNA extraction.  
The remaining solution was submitted again to another spin but this time at 17226 
RCF for 5 minutes. The supernatant was discarded and the urinary sediment suspended in 
600 μL of RLT Buffer + β-mercaptoethanol (10%) in order to lyse the cells.  Samples were 
stored at -80°C. 
2.3.1 DNA extraction from cells of the urinary sediment  
Performed with the DNA extraction kit by MagAttract ® DNA Blood Midi M48 
(Qiagen ®). The elution volume of DNA was 75μL on Tris-EDTA (TE). The protocol is the 
same as described above for DNA extraction from peripheral blood section. 
2.3.2 RNA extraction from cells of the urinary sediment 
Frozen samples, previously stored at -80°C, were thawed at 4°C, homogenized and 
subjected to centrifugation at maximum speed for 3 minutes. The supernatant (350μL) was 
placed on the shaker QIACube (Qiagen ®).  
RNA was extracted using the RNeasy Mini Kit. RNA (Qiagen ®) was eluted in 50 μL 
of RNase-free water (RNFW) and stored at -80°C. 
2.4 HLA typing by Luminex® (LABType® SSO Typing Tests) 
The HLA typing began with the amplification of the coding regions of HLA-A, HLA-B, 
HLA-C and HLA-DR alleles using the polymerase chain reaction (PCR).  
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The primers used for the amplification are biotinilated. The single stranded product is 
then hybridised with a multiplex of up to 100 beads, all of which can be uniquely identified by 
their internal dyes and all of which are selectively coated with specific oligonucleotide 
sequences. These beads are made of polystyrene and each one is internally dyed with a 
unique combination of red and infrared dye.  
The combination of different intensities of the two dyes, allows the identification of 
each bead by its unique signature when excited by a laser beam. A red laser is used to excite 
and therefore identify the specific bead and a green laser is used to excite and therefore 
identify any reporter dyes captured on the beads during the assay. In this case, the molecule 
chosen was Streptavidin – Phycoerytherin (SAPE) conjugate, with Streptavidin binding to the 
biotin used to label the primers and Phycoerytherin serving as the reporter dye. 
2.4.1 HLA genes amplification 
The amplification of the HLA genes was accomplished with One Lambda® 
amplification kits, more specifically, the D-mix (LABType® Primer Sets and D-mix) with the 
respective amplification primers  and  TaqPolimerase (5U/μL) from ABgene. 
A 96 well plate was prepared with 9 µl of the Master Mix and 1 µl of DNA in each 
well. After sealing the plate, the amplification occurred in the C1000TM Thermal Cycler 
with the amplification program showed in Table III. 
Table III - HLA genes PCR amplification program. 
 
 
Step 
 
 
Temperature(°C) 
 
 
Time (min) 
 
 
Cycles 
 
 
1 
 
 
96 
 
 
03:00 
 
 
1 
 
 
 
 
 
 
 
2 
 
 
 
96 
 
 
00:20 
 
 
 
5 
 
 
60 
 
 
00:20 
 
 
72 
 
 
00:20 
 
 
 
 
3 
 
 
96 
 
 
00:10 
 
 
 
30 
 
 
60 
 
 
00:15 
 
 
72 
 
 
00:20 
 
 
4 
 
 
72 
 
 
10:00 
 
 
1 
 
 
5 
 
4 
 
 
∞ 
 
 
1 
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2.4.2 Denaturisation/Neutralization and Hybridization  
At the end of the amplifications, the resulting products were denatured and 
neutralized with the denaturing buffer and neutralizing buffer, respectively.  As described 
above, the next step was the hybridization with the beads that occurred at 60ºC during 15 
minutes. These beads are coated with specific oligonucleotide HLA sequences for each 
locus: locus A – RSSOH1A; locus B – RSSOH1B; locus C – RSSOH1C; locus DR – RSSOH2B1. 
Subsequently, 2 washing steps were needed to proceed to the addition of 
Streptavidin – Phycoerytherin (SAPE) solution (Stock SAPE and SAPE Buffer), as explained 
above it allows us to detect the biotinilated PCR products. In order to allow biotin and 
Streptavidin bonding, an incubation at 60ºC for 5 minutes was required. 
Finally, after some more washing steps, 60 µl of washing buffer were added to each 
well and all products were transferred into an ELISA plate with conical bottom.  
The plate was read on the LABScan™ 100 and the fluorescence variations were 
interpreted on the LabTools program from One Lambda®. 
2.4.3 Anti-HLA Class I and Class II Antibody screening in blood serum 
Beads coated with anti-HLA Class I and Class II purified antigens were used to detect 
anti-HLA antibodies in the serum. The information provided by these beads can be deduced 
in LABScanTM100 (Luminex®). 
The serum samples were defrosted and centrifuged at maximum speed (Eppendorf, 
Centrifuge 5415R). The following step was to incubate the samples (diluted 1:2) with the 
LABScreen® Mixed (2,5 μL) beads in the dark and with moderate stirring on an ELISA plate 
of 96 wells for 30 minutes. This step allows the antigens to bind to the respective antibodies 
present in the blood serum of each sample. 
 When the incubation was completed, there was a need to execute some washing 
steps to remove the beads that remain unbounded. This wash was done with washing buffer 
1X. 
The analysis is based on fluorescence so there is a need to add a fluorophore, in this case 
was Phycoerytherin (PE) conjugated with anti-IgG, that binds to the antibodies that were 
bound to the antigens present in the beads.  Another incubation was required under the 
same conditions as the first one. 
Again, after the incubation, it was necessary to complete some washing steps and 
following the last wash, 80 µL PBS 1x were added. The plate was placed on the 
Methods  
 
28 
 
LABScanTM100 equipment and the results analysed on the HLA fusion program from One 
Lambda®. 
2.4.4 Anti-HLA Class I and Class II Antibody screening in urine 
The screening of antibodies in the urine was completed by taking 1 mL of supernatant 
and adding 1mL of PBS 2x. The next step was the incubation overnight, in the same 
conditions as before, with the LABScreen® Mixed beads but this time with 10 μL. The next 
steps are exactly the same as in the antibody screening in the serum after the incubation.  
This was a method developed in our lab and might need some small changes. 
2.5 Relative quantification in cells from the urinary sediment 
 2.5.1 Reverse-transcription PCR 
This type of PCR is used to obtain complementary DNA (cDNA) from extracted 
RNA, in this case, RNA from urinary sediment cells. This is possible because the polymerase 
present in this reaction is a reverse transcription polymerase.  
The reverse transcription Kit used was the iScript™ Reverse Transcription Supermix 
(Bio-Rad). The process begins with the addition of the extracted RNA (8 µl) to the 5X 
iScript™ Reverse Transcription Supermix (4 µl) and RNFW (8 µl). The synthesis reactions were 
performed in the DNA Engine® Thermal Cycler (Bio-Rad) with the PCR program displayed 
on Table IV. 
Table IV- PCR program used in the reverse transcription reaction using the iScript™ 
Reverse Transcription Supermix. 
 
 
Steps 
 
 
Temperature (ºC) 
 
 
Time (min) 
 
 
1 
 
 
25 
 
 
10:00 
 
 
2 
 
 
42 
 
 
60:00 
 
 
3 
 
 
85 
 
 
05:00 
 
 
4 
 
 
4 
 
 
∞ 
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2.5.2 Normalization 
Data normalization in real-time RT-PCR is a major step in gene quantification analysis 
since it compensates intra and inter-kinetic RT-PCR variations (sample-to-sample and run-
to-run variations). 
The normalization was achieved with the evaluation of gene expression levels of 
reference genes.  It is assumed that the expression of these reference genes does not differ 
between reads. 
In order to select  the two reference genes, random samples were used  in the 
reactions with each one of 7 genes that could be used as reference gene:  β- Actin (ACTB), 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), Ubiquitin C (UBC), β -2- microglobulin 
(B2M), subunit 1 of splicing factor 3a (SF3A1), ribosomal subunit 18S (18S rRNA) and Cytochrome 
C -1 (CYC1) and proceeded to Real-Time PCR reactions. 
The results obtained in these reactions were analysed on the GeNorm Program 
(PrimerDesign) that selected the two reference genes suitable for the samples being studied.  
Then, Real-Time PCR (RT-PCR) reactions of all samples with reference genes were 
performed and the results were analysed again on the GeNorm Program but this time to 
acquire the normalization factor for each sample. The normalization factor is crucial to 
calculate the Normalize gene expression values (NGE) when examining the genes of interest. 
2.5.3 Real-Time PCR reactions 
Real-time Polymerase Chain Reaction  allows monitoring of  the progress of the PCR 
as it occurs, therefore the data is collected throughout the amplification process, rather than 
at the end of the PCR. In this type of PCR, a fluorescent reporter is used and an increase in 
the reporter fluorescence signal is directly proportional to the number of amplicons 
generated. The more starting copies of the nucleic acid target, sooner a significant increase 
in fluorescence is observed. 
The fluorescent marker selected in this work was SYBR® Green I (Bio-Rad), which 
evenly binds to double-stranded DNA molecules, emitting a fluorescent signal with a defined 
wavelength. The signal is detected during the extension step of the PCR reaction in real 
time. Signal intensity increases with increasing number of cycles due to the accumulation of 
the PCR product. 
However, SYBR® Green I have some disadvantages as it may generate false positive 
signal as the SYBR Green I dye binds to any double-stranded DNA, it can also bind to 
nonspecific double-stranded DNA sequences. 
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The RT-PCR reactions were executed on the Light Cycler® 480 (Roche) equipment 
and the Master Mix for these reactions contained 2x QuantiTect SYBR Green PCR Master 
Mix (QIAGEN) (5 µl), RNFW (2 µl) and 10x QuantiTect Primer assay (QIAGEN) (1µl).  
Then the cDNA of each samples was added to a well of a 96 Light Cycler® 480 
Multiwell Plate (2 µl) making the final volume of each reaction 10 µl. All interest genes 
studied as well as the respective reference genes are listed below on Table V and the 
amplification program is presented on Table VI. 
Table V - List of all the interest genes studied as well as the respective reference genes. 
 
 
Reference Genes 
 
 
Interest Genes 
GAPDH 
(QT00079247) 
CYC1 
(QT00209454) 
CXCL10 
(QT01003065) 
CXCL9 
(QT00013461) 
TGF-β1 
(QT00000728) 
GATA3 
(QT00095501) 
IL4 
(QT00012565) 
CD19 
(QT00203826) 
CD79B 
(QT00203651) 
IL10 
(QT00041685) 
TNF3 
(QT01079561) 
FOXP3 
(QT00048286) 
IL17 
QT00009233 
 
 
Table VI - Real-Time PCR amplification program. 
 
 
Steps 
 
 
Temperature (ºC) 
 
 
Time (min) 
 
Cycles 
 
 
1 - Enzime Activation 
 
 
95 
 
 
15:00 
 
 
1 
 
 
2 – Amplification 
 
 
95 
 
 
00:15 
 
 
 
50 
 
 
55 
 
 
00:30 
 
 
72 
 
 
00:30 
 
 
3 - Melting curve 
 
 
65 - 95 
 
 
- 
 
 
1 
 
The results were analysed on the Light Cycler® 480 software (Roche) and the two 
main aspects of analysis were the melting curves and the crossing points obtained. The 
melting curves reflects the specificity of the amplification and the crossing points are used to 
determine the relative quantity (RQ) of each gene by applying the RQ= 2-ΔCp formula. The 
Normalized gene expression (NGE) values are given by the quotient between the RQ for 
the gene of interest and the normalization factor for each sample.  
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2.6 Statistical analysis 
 The presentation of results is done using the mean ± standard deviation for each 
group. The results were submitted to U Mann-Whitney test or Fisher´s exact test and 
considered statistically significant when p<0.05. The normalized gene expression values were 
also analysed by the receiving operator characteristics (ROC) curves for specificity and 
sensitivity. The software used was the IBM SPSS® Statistics 20. 
  
 
 
 
 
 
 
 
 
 
 
3. Results 
  
3. Results 
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3.1 Demographic Data and Clinical Features of the population in study 
 The demographic data displayed on Table I reveals a similarity between both groups 
despite the sole criterion applied being the fact that the patients have been submitted to 
renal transplant for more than two years. As a result of this homogeneity, the influence of 
characteristics like, body-mass index or even the time-post transplant, in the results 
obtained is greatly reduced. 
 Table II exhibits the clinical features of both groups of patients. The distribution of 
patients into both groups was based on the diagnostic made by the clinicians and mainly by 
the serum creatinine levels that are clearly elevated on chronic rejection group. In terms of 
diabetes and ischemia both groups show similar incidence and until the samples collection 
none patients revealed any signs of active infections by cytomegalovirus. The increased 
percentage of patients with previous episodes of acute rejection on chronic rejection group 
confirms the importance of acute rejection in the development of this condition. 
3.2 Donor/Receptor mismatches 
 The Donor/Receptor compatibilities are shown on table VII. The compatibilities refer 
to the HLA match typing of both donor and receptor for each group. The HLA Class I loci 
analysed were “locus A” and “locus B” with 4 maximum possible mismatches, two for each 
locus. The HLA Class II locus tested was “locus DR” with a maximum of two possible 
matches between donor and receptor. 
Table VII - Donor/Receptor compatibilities. 
 
 
Normal Function Group 
 
 
Chronic Rejection Group 
 
 
HLA Class I (A/B) 
Mismatches 
(Mean) 
 
 
HLA Class II (DR) 
Mismatches 
(Mean) 
 
 
HLA Class I(A/B) 
Mismatches 
(Mean) 
 
 
HLA Class II(DR) 
Mismatches 
(Mean) 
 
 
2,62 
 
 
0,69 
 
 
2,64 
 
 
0,62 
 
 Concerning HLA Class I loci, the two groups presented an average of 2,62 
mismatches for normal function group (NF Group) and 2,69 for chronic rejection group (CR 
group)  out of four possible matches, as explained before.  
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In contrast the average mismatches for HLA Class II locus were 0.69 for NF group 
and 0,62 for CR group  indicating that  the majority of the patients of both groups were 
compatible with their donor for HLA Class II locus.  
It is important to refer that there were five patients in the NF Group that had 6 
mismatches with their donor showing no compatibility with their donor. In CR group only 
one patient exhibited this condition.  
3.3 Anti-HLA antibody screening in the serum 
 The antibody screening in the serum of renal transplant patients with normal function 
(NF Group) revealed a low percentage of anti-HLA Class I antibodies and a slightly higher 
percentage of anti-HLA Class II antibodies (Table VIII). 
 Regarding the renal transplant patients who have been diagnosed with chronic 
rejection (CR group) the percentage of anti-HLA Class I antibodies was even lower 
comparing to NF group. In contrast, the percentage of anti-HLA antibodies Class II is on a 
small scale higher in CR group (Table VIII). 
Table VIII - Percentage of anti-HLA antibodies found in the serum of renal transplant 
patients.  
 
 
 
Anti-HLA antibodies Class I 
 
 
Anti-HLA antibodies Class II 
 
 
Positive (%) 
 
 
Negative (%) 
 
 
Positive (%) 
 
 
Negative (%) 
 
 
NF Group 
 
 
12,7 
 
 
87,3 
 
 
16,9 
 
 
83,1 
 
 
CR Group 
 
 
3,7 
 
 
96,7 
$ 
 
18,5 
 
 
81,5 
 
Legend: NF - Normal Function group; CR - Chronic Rejection group.  
3.4 Anti-HLA Antibodies vs.  HLA Mismatches 
 Table IX shows the association between the number of HLA Class I mismatches and 
the presence of anti-HLA Class I antibodies in the serum of renal transplant patients. It is 
clear that the higher number of mismatches is linked with the detection of circulating anti-
HLA Class I antibodies. In the CR group, with only one patient with anti-HLA Class I 
antibodies, no relevant information can be withdrawn.  
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Table IX- Relationship established between the number of HLA Class I mismatches and the 
number of patients with presence of anti-HLA Class I antibodies. 
Nº of 
mismatches 
 
 
Normal Function Group 
 
 
Chronic Rejection Group 
Nº of patients 
with Class I 
mismatches 
 
 
Nº Patients 
with anti-
HLA Class I 
antibodies  
Nº of 
patients with 
Class I 
mismatches 
 
 
Nº Patients 
with anti-
HLA Class I 
antibodies  
 
 
4 
 
 
12 
 
 
2 
 
 
6 
 
 
0 
 
 
3 
 
 
26 
 
 
4 
 
 
6 
 
 
1 
 
 
2 
 
 
21 
 
 
2 
 
 
12 
 
 
0 
 
 
1 
 
 
5 
 
 
1 
 
 
2 
 
 
0 
 
 
0 
 
 
2 
 
 
0 
 
 
0 
 
 
0 
 
Table X- Relationship established between the number of HLA Class II mismatches and the 
number of patients with presence of anti-HLA Class II antibodies. 
Nº of 
mismatches 
 
Normal Function Group 
 
Chronic Rejection Group 
Nº of patients 
with Class II 
mismatches 
 
Nº Patients 
with anti-
HLA Class II 
antibodies  
Nº of patients 
with Class II 
mismatches 
 
Nº Patients 
with anti-
HLA Class 
II antibodies  
 
 
2 
 
 
7 
 
 
1 
 
 
4 
 
 
0 
 
 
1 
 
 
29 
 
 
9 
 
 
9 
 
 
2 
 
 
0 
 
 
24 
 
 
2 
 
 
13 
 
 
3 
 
The association between the number of HLA Class II mismatches and the number of 
patients with presence of HLA Class II antibodies is represented in Table X. The number of 
patients with no mismatches for Class II is clearly superior comparing to Class I mismatches. 
3.5 Anti-HLA antibody screening in urine of renal transplant patients 
The antibody screening in the urine of renal transplant patients revealed that more 
than half of the patients in the chronic rejection group exhibited anti-HLA Class I antibodies 
(Table XI). The percentage of these antibodies in normal function group stayed around 20%.  
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The percentage of anti-HLA Class II antibodies for the CR Group in urine is around 
22% whereas in NF group is 24%. 
Table XI- Anti-HLA antibodies percentage found in urine of renal transplant patients 
 
 
 
Anti-HLA Class I antibodies  
 
 
Anti-HLA Class II antibodies  
 
 
Positive (%) 
 
 
Negative (%) 
 
 
Positive (%) 
 
 
Negative (%) 
 
 
NF Group 
 
 
24 
 
 
76 
 
 
15,5 
 
 
84,5 
 
 
CR Group 
 
 
51,89 
 
 
48,11 
 
 
22,2 
 
 
77,8 
 
 
 
Legend: NF- Normal Function group; CR- Chronic Rejection group 
3.6 Comparing anti-HLA antibodies screening in urine with anti-HLA antibodies 
screening in the serum 
 The different results obtained in antibody screening in the serum and in urine are 
displayed on Table XII. The variances of percentages for anti-HLA Class I antibodies are the 
most obvious, with special emphasis for the CR group where the percentage goes from 3,7% 
in the serum to 51,89% in urine.  These differences are statistically significant. 
 Regarding anti-HLA Class II antibodies the differences are less evident with the 
biggest change happening in CR group where the percentage of anti-HLA Class II antibodies 
goes from 18,5% in the serum to 22,2% in urine. The results had no statistical significance 
(Table XII). 
Table XII - Comparison of HLA antibody percentage in the serum and urine   
Group 
 
 
HLA Class I antibodies (%) 
 
 
HLA Class II antibodies (%) 
 
 
Serum 
 
 
Urine 
 
 
p value 
 
 
Serum 
 
 
Urine 
 
 
p value 
 
 
FN group 
 
 
12,7 
 
 
24  
 
p=0,03 
 
 
16,9 
 
 
15,5  
 
p>0,05  
 
CR group 
 
 
3,7 
 
 
51,89 
 
 
18,5 
 
 
22,2 
 
 
 
Legend:  The differences were considered statistically significant when p<0.05 for the Fisher’s exact 
test. NF- Normal Function group; CR- Chronic Rejection group. 
Table XIII demonstrate that the patients with anti-HLA antibodies in the serum are 
not necessary the same with anti-HLA antibodies in the urine. This becomes evident for the 
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NF group when the number of patients with anti-HLA antibodies in urine is 15 and in serum 
is only 9. The difference is even greater in CR group where 12 patients have anti-HLA 
antibodies in urine whereas in the serum this number is only 4.  
Table XIII - Comparison of anti-HLA antibody detection in the serum and urine for each 
group of renal transplant patients. 
 
Legend: NF - Normal Function group; CR - Chronic Rejection group. 
3.7 Gene expression in urinary sediment 
3.7.1 CXCL10, CXCL9 and TGF-β1 
 The normalized gene expression (NGE) values of genes encoding the chemokine’s 
CXCL10 and CXCL9 in chronic rejection group (CR group) are increased in comparison with 
normal function group (NF group) and  the differences are considered statically significant 
with a p value of p=0.03 and p=0.04 (Figure 7). The control group exhibits NGE values 
higher than both groups for CXCL9 gene and lower in CXCL10 gene. 
Regarding the gene encoding TGF-β1, NGE levels are also found higher in CR group 
comparing to NF group, obtaining significant differences with a p=0.02. NGE levels of the 
control group for the gene encoding TGF-β1 are lower than both NF and CR groups. 
 
 
 
 
NF group 
  
 
CR group 
Urine 
 
 
Serum 
 
 
Patients with 
anti-HLA 
antibodies 
 
 
Patients 
without anti-
HLA 
antibodies 
 
 
Patients with 
anti-HLA 
antibodies 
 
 
Patients 
without anti-
HLA 
antibodies 
Patients 
with anti-
HLA 
antibodies 
9 6 4 2 
Patients 
without 
anti-HLA 
antibodies 
15 41 12 9 
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Figure 7- Box and whiskers plots of mRNA levels, in the urinary sediment, of CXCL10, 
CXCL9 and TGF-β1. The horizontal line within each box represents the median, the bottom and 
top represent the 25th and 75th percentile values, and the thin vertical bars extend to the minimum 
and maximum values 0,03, 0,04 and 0,02 respectively .The NGE values of CXCL10, CXCL9 and TGF-β1 
are superior for CR group, with a p value of  * represents the results considered statistically 
significant for U Mann-Whitney test (p<0,05).  NGE – Normalized Gene Expression; NF – Normal 
Function Group; CR – Chronic Rejection Group; CTRL – Control Group; TGF-β1 – Gene encoding 
Tumour Growth Factor-β; CXCL10 – Gene encoding C-X-C motif chemokine 10; CXCL9 – Gene 
encoding C-X-C motif chemokine 9. 
The analysis of receiver operating characteristic (ROC) curves, in terms of specificity 
and sensitivity, allows the assessment of the predicting value for chronic rejection in each 
gene.  CXCL10 gene displayed an area under the curve (AUC) of 74,73% and the best 
association of specificity and sensitivity was 87,0% and 62,5%, respectively.  
The area under the ROC curve for CXCL9 was 68,04% with  the top correlation 
between specificity and sensitivity being 96,4% and 45,0%, respectively. Regarding TGF-β1, 
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the finest association for specificity and sensitivity was 53,0% and 72,0%, in that order. The 
AUC for TGF-β1 was 63,09%. 
 
 
 
 
Figure 8- ROC curves (95% confidence interval)  for sensitivity and specificity of CXCL9, 
CXCL10 and TGF-β1 to evaluate their diagnostic value for chronic rejection.  CXCL10 
gene showed the biggest predictive potential among the three genes with an AUC of 74,73% and a 
specificity of 87,0% and a sensitivity of 62,5. ROC, receiver operating characteristic; AUC- area 
under the curve. 
3.7.2 GATA3 and IL4  
The NGE values of the T-cell-specific transcription factor GATA3 are found superior 
for NF group rather than for CR group with a significant  p value = 0.04. The Control Group 
unveils a higher expression than both CR and NF groups.  In contrast, the gene encoding 
interleukin 4 showed a higher prevalence in CR group comparing to NF group, however, no 
statistical significance was found. No amplification was verified for IL4 in control group 
(Figure 9).  
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Figure 9- Box and whiskers plots of mRNA levels, in the urinary sediment, of GATA3 
and IL4. The horizontal line within each box represents the median, the bottom and top represent 
the 25th and 75th percentile values, and the thin vertical bars extend to the minimum and maximum 
values. GATA3 NGE values are increased for NF group with statistical significance (p=0,04).On the 
other hand, NGE levels of IL4 are higher for CR group but no statistical significance was achieved. 
 * represents the results considered statistically significant for U Mann-Whitney test (p<0,05). 
 NGE – Normalized Gene Expression; NF – Normal Function Group; CR – Chronic Rejection 
Group; CTRL – Control Group; GATA3 – Gene encoding  T-cell-specific transcription factor GATA3;  
IL4 – Gene encoding interleukin 4.  
 Concerning the ROC curves for GATA3 and IL4, the AUC found were 61,96% and 
50,94%, respectively. In terms of specificity and sensitivity, the optimal correlation for GATA3 
was 44,3% in specificity and 61,8% in sensitivity. IL4 ideal association was 30,2% for specificity 
and 92,3% for sensitivity. 
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Figure 10- ROC curves (95% confidence interval) for sensitivity and specificity of GATA3 
and IL4 to evaluate their diagnostic value for chronic rejection. Neither of the two genes 
exhibited a significant diagnostic value for chronic rejection. The AUC for GATA3 was 61,96% and for 
IL4 this value was 50,94%. ROC – receiver operating characteristic; AUC – area under the curve. 
3.7.3 CD79B and CD19 
 
Figure 11- Box and whiskers plots of mRNA levels, in the urinary sediment, of CD79B 
and CD19. The horizontal line within each box represents the median, the bottom and top 
represent the 25th and 75th percentile values, and the thin vertical bars extend to the minimum and 
maximum values. CD79B and CD19 show increased NGE values for CR group comparing to NF 
group. The differences found are statistically significant (p=0.03 and p<0.0001, respectively).  
* represents the results considered statistically significant for U Mann-Whitney test (p<0,05).  
NGE – Normalized Gene Expression; NF – Normal Function Group; CR – Chronic Rejection Group; 
CTRL – Control Group;  CD79B – Gene encoding the Cluster of Differentiation 79B ; CD19 – Gene 
encoding Cluster of Differentiation 19.  
Figure 11 shows the normalized gene expression levels for CD79B and CD19 genes. 
Both genes reveal a greater prevalence in CR group instead of NF group. These difference 
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are considered statistically significant with a value of p=0.03 for CD79B and p<0.0001 for 
CD19. 
The NGE levels of control group are lower than NF and Cr groups in CD79B gene, 
however, in CD19 gene the normalized gene expression values are increased comparing to 
NF and CR group NGE values. 
 The ROC curve For CD79B gene showed an AUC of 59,97% and the prime 
correlation point for specificity and sensitivity was 72,9% and 50,0%, respectively. The 
optimum association between specificity and sensitivity, for CD19 gene, was 72.5% specificity 
and 77,8% sensitivity. CD19 also exhibited an AUC of 79,15 %. 
  
 
Figure 12- ROC curves (95% confidence interval) for sensitivity and specificity of CD79B 
and CD19 to evaluate their diagnostic value for chronic rejection. CD19 gene displayed  the 
best predictive value among all genes evaluated with the specificity and sensitivity values being 72,5% 
and 77,8%, respectively. The AUC was 79,15%.  ROC-receiver operating characteristic; AUC-area 
under the curve. 
3.7.4 IL10, TNF3 and FOXP3 
The gene encoding IL10 shows a greater propensity for CR Group and, despite the low 
number of samples that had amplification, the differences between the NF and CR groups 
are statistically significant with a value of p=0.02. None of the samples in control group had 
amplification for IL10 gene.  
 TNF3 gene also had increased NGE values for the chronic rejection group with 
statistical significance, presenting a p value =0.0002. The control group exhibited NGE values 
superior than normal function and chronic rejections groups. 
 Finally, FOXP3 gene revealed higher NGE levels for the normal function group when 
compared to CR group but no statistical significance was achieved. The NGE values of 
control group gene were higher than both groups (Figure 13). 
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Figure 13- Box and whiskers plots of mRNA levels, in the urinary sediment, of IL10, 
TNF3 and FOXP3. The horizontal line within each box represents the median, the bottom and top 
represent the 25th and 75th percentile values, and the thin vertical bars extend to the minimum and 
maximum values. The NGE values of both IL10 and TNF3 are superior for CR group comparing to 
NF group. The results are statistically significant with a p value of 0.02 and 0.002, respectively. 
Oppositely, The NGE values of FOXP3 gene are increased in NF group, however, no statistical 
significance was observed. 
 * represents the results considered statistically significant for U Mann-Whitney test (p<0,05). NGE-
Normalized Gene Expression; NF – Normal Function Group; CR – Chronic Rejection Group; CTRL 
– Control Group; IL10 – Gene encoding Interleukin-10; TNF3 – Gene encoding Tumour Necrosis 
Factor-3; FOXP3 – Gene encoding the transcription factor FOXP3. 
 IL10 ROC curve revealed an area under the curve of 76,23%. The best correlation 
for specificity and sensitivity was 82,4% and 66,7%, respectively. These values for TNF3 were 
76,2% and 68,0%. The AUC for TNF3 was 72,25%. 
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Figure 14- ROC curves (95% confidence interval) for sensitivity and specificity of IL10 
and TNF3 to evaluate their diagnostic value for chronic rejection. Despite the low 
amplification, IL10 gene exhibited decent predictive values for chronic rejection presenting an AUC 
of 76,23% with the specificity and sensitivity values being 82,4% and 66,7%, respectively. TNF3 gene 
also showed a decent predictive value for chronic rejection with an AUC of 72,25% with a specificity 
of 76,2% and a sensitivity value of 68,0%. ROC – receiver operating characteristic; AUC – area under 
the curve. 
The IL17 gene was also tested, however, very few samples or even none amplified so 
it was not possible to proceed to any statistical analysis. 
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In the last 20 years, the short-term results of kidney transplantation have improved 
considerably, mainly due to the use of modern immunosuppressive agents in doses sufficient 
to prevent acute rejection (136, 137).  Despite these improvements, a significant percentage 
of allografts develop a progressive decline of renal function and fail within a decade making 
chronic rejection the main cause for late graft loss (138). 
 The mechanisms behind chronic rejection are not completely understood, therefore 
the extensive studies to better characterize this condition are extremely important and bring 
us closer to create strategies for improving kidney transplant in terms of survival, monitoring 
and prognostic (55). 
 Currently, renal transplant monitoring is done by regular clinical consultation. The 
samples evaluated in this study were from patients followed by the Renal Transplant Unity 
from the “Centro Hospitalar Universitário de Coimbra” E.P.E.   As explained above, the only 
criterion for inclusion of the samples in the study was that the patients have undergone 
kidney transplant for more than two years. Posteriorly, the samples were divided into two 
groups: patients who have a normal graft function and patients with chronic rejection. This 
division was based on the creatinine levels and on the diagnostic of chronic rejection made 
by the clinicians. However it is important to note that sometimes the adverse effects of 
immunosuppressive drugs are mistaken with chronic rejection clinical manifestations leading 
to incorrect diagnostics.  
Apart from the resemblance intra and inter-group, one important aspect to retain 
from Table I and II, is the higher percentage of previous acute rejection episodes in the CR 
group which is in agreement with current literature arguing that acute rejection facilitates 
the development of chronic rejection (64). 
Despite the satisfactory homogeneity found in both groups, in future works  more 
restrictive criteria should be applied when collecting the samples, in order to reduce the 
impact factor of demographic and clinical features in the results obtained. Moreover, future 
studies should include a higher number of patients with chronic rejection to balance the 
number of samples in each group. 
Another limitation of this study lies on the control group only being composed by 
healthy individuals. A more suitable control group would be a set of individuals that were 
submitted to a kidney transplant and have a functional graft, but do not require any 
immunosuppressive agents to survive. These patients are registered in a worldwide database 
but it was impossible to get blood and urine samples from these patients. 
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 As explained before, the HLA system is highly polymorphic making the search for a 
total compatible donor very challenging. It has been verified that HLA mismatches, specially 
the HLA-mismatches at the HLA-A, B and DR loci, influence renal transplant recipients 
outcomes (139, 140). 
 It is only natural that the amount of HLA mismatches was taking into account when 
choosing the suitable donor, explaining why the number of HLA mismatches found in both 
groups was not significant and the total of donor/receptor HLA mismatches between the 
two groups for either Class I and Class II loci was very similar (Table VII). This is crucial since 
the recognition of mismatched donor histocompatibility antigens is the key event that, 
eventually, triggers an immune response initiating allograft rejection (141). 
 Furthermore, until some years ago the first criterion for donor eligibility in terms of 
donor/receptor mismatches was the number of mismatches in HLA Class II “DR” locus, 
explaining the low number of mismatches for this locus found in both groups (Table VII). 
The importance of humoral sensitization against foreign HLA antigens has been 
recognized since the beginning of transplant medicine (142). Over the past two decades, the 
advances in molecular approaches and in the technology available, resulted in implementation 
of sensitive assays for the  screening and identification of anti-HLA antibodies (143). 
Several studies demonstrated that the development of anti-HLA antibodies, pre or 
post-transplant, has a negative effect on graft survival (144-147). Most of these studies focus 
on donor-specific anti-HLA antibodies and on their ability to bind HLA antigens on allograft 
endothelium activating either the classic complement pathway or induce antibody-dependent 
cell-mediated cytotoxicity (148, 149).  
Nevertheless, the contribution of non-donor specific antibodies cannot be ignored as 
in some patients the levels of these antibodies rise in rejection episodes suggesting a non-
specific immune upregulation (150, 151). 
In this study, the frequency of anti-HLA antibodies Class I detected in the serum of 
renal transplant patients was surprisingly higher in the normal function group when 
compared to the same frequency in chronic rejection group which was particularly low. The 
anti-HLA Class II antibodies frequency are considerably higher than anti-HLA Class I 
antibodies frequency in both groups. This goes in agreement with the literature suggesting 
that anti-HLA Class II antibodies detected in the serum have a more predictive value for 
injuries in microcirculation causing loss of graft function (152). 
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The association between a higher number of HLA mismatches and the amount of 
patients with anti-HLA Class I antibodies was validated for NF group (Table IX) showing that 
HLA mismatches are able to induce antibody production. 
 On the other hand for HLA Class II antibodies this association was not confirmed 
suggesting that HLA mismatches have different immunogenicity’s. This has been described in 
some studies and also has been discussed the ability of some HLA mismatches to promote 
graft tolerance, under specific clinical conditions (153, 154). Additionally, Platt (155) 
theorized that the antibodies detected in the serum may be the ones with low affinity that 
are unable to bind to the graft, therefore not the ones causing graft rejection.   
Considering the HLA mismatches different immunogenicity’s, the low frequencies of 
HLA antibodies detected in the serum and also the theory that antibodies detected might 
not be the ones acting on the graft, there was a need to take a different approach and urine 
came as a natural alternative since it is produced in the kidneys and is easily collected by 
non-invasive methods. 
 The antibody screening methodology applied in the urine of renal transplant patients 
was developed from the standard procedures in our lab, normally used to perform antibody 
screening in the serum. Surprisingly decent results were obtained from the screening in 
urine, with a statistically significant increase of anti-HLA Class I antibodies frequency when 
compared to the frequency of the same antibodies detected in the serum of patients 
diagnosed with chronic rejection (Tables XII and XIII). 
In 2005, Yi-Ping et al. (156) proposed a mechanism where anti-HLA Class I antibodies 
bind to HLA Class I molecules on the surface of graft endothelial cells stimulating cell 
proliferation and up-regulating cell survival genes promoting chronic rejection development. 
 Furthermore, Ali et al. (154) confirmed the capacity of anti-HLA Class I antibodies to 
induce endothelial cells proliferation after transplantation by a mechanism that facilitates the 
development of an inflammatory response due to the release of inflammatory cytokines and 
chemokines, like CXCL10 and CXCL8 by endothelial cells and it also favors cellular 
rejection, as a result of expression of cell-surface adhesion molecules resulting in increased 
addition of monocytes to the kidney endothelium (157, 158).  
The high frequency of anti-HLA Class I antibodies found in urine of CR group 
patients can result from the mechanism described above, with the anti-HLA Class I 
antibodies moving into the urine when they lose adherence to the endothelium allowing 
their detection in urine but not in the serum.  
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In Table XIII, it is possible to observe the discrepancies in both urine and serum 
analyses, with 15 patients in NF group and 12 in CR group with detectable antibodies in the 
urine but not in the serum.  
The 15 patients in NF group should be followed and their urine and serum tested for 
anti-HLA antibodies in the next few years, to understand if they are in a process of 
developing chronic rejection. If so, this could be a breakthrough in terms of chronic 
rejection diagnostic as  it would be a simple, non-invasive, low cost method that  would  
allow a premature diagnostic of chronic rejection, contrasting with the current methods 
available (essentially biopsies) that frequently diagnose this condition when it is irreversible. 
Another point of interest is the production of these anti-HLA antibodies found in the 
urine of renal transplant patients. This has brought back B cells to the center of transplant 
immunology as they are the major producers of alloantibodies.  
Thaunat et al. (95) noticed that the inflammatory infiltrated of kidney grafts, 
explanted because of terminal chronic rejection, had turn into organized ectopic lymphoid 
tissues, harbouring the maturation of a local immune response responsible for tissue 
destruction.  
The formation of this functional ectopic germinal center, a process known by 
lymphoid neogenesis, permits the maturation of B cells into memory B cells and plasma cells, 
the last ones being the cells responsible for alloantibodies production. Oppositely, if the 
formation of the ectopic tertiary lymphoid tissue was incomplete the maturation of B cells 
was also blocked. 
 The fact that this maturation can be inhibited, unveils new targets for novel 
therapeutic approaches. In the same study, it was also verified that the circulating antibodies 
were different from the ones produced locally in the graft, denoting the existence of two 
different immune responses targeting different antigens.  
The immune system has the capacity to produce a local adaptive immune response in 
the presence of secondary lymphoid organs. This immune response leads to the release of 
inflammatory chemokines who recruit naïve B cells into the graft originating the tertiary 
lymphoid tissue also known as B-cell cluster. Then, as explained above, if the neogenesis is 
completed, the ectopic germinal center becomes functional and the accumulated B cells can 
mature into memory B cells and to plasma cells.  
Moreover, the B cells from this tertiary tissue can also locally promote T-cell 
response, as they function as antigen presenting cells, creating all the conditions for tissue 
destruction and  for development of even more chronic inflammatory processes (159).  
Discussion  
 
50 
 
Alternatively, other studies show that B cells can promote tolerance but the 
mechanisms behind it are not entirely understood (160, 161). 
 The results obtained by qRT-PCR seem to go accordingly to the mechanism 
proposed above. We evaluated the gene expression in the cells of the urinary sediment of 
the immunological mediators of inflammatory state and fibrosis of renal tissue: CXL10 and 
CXCL9 and also one of the most important cytokines of the immune system TGF-β1 to 
confirm the aggravated inflammation of the graft in CR group.  
The NGE levels of all three genes came out with superior values in the chronic 
rejection group with significant differences towards NF group (Figure 7). These results go in 
agreement with previous work done in our laboratory and also with the literature available 
(162-164). In fact, CXCL10 has been sustained as a decent biomarker for rejection, mainly, 
due to their role in regulating  chemotaxis during the inflammatory response resulting from 
allograft rejection after transplantation (165).  
The value of CXCL10 as a suitable biomarker for chronic rejection was verified by the 
ROC curve analysis of the NGE values where CXCL10 proven to be the best among the 
three genes with a specificity of 87,0% and a sensitivity of 62,5% corresponding to an AUC of 
74,73% (Figure 8)  which is a very satisfying value for a marker.  
Although the information available suggest that CXCL9 can have more value as a 
marker for acute rejection, the ROC curves analysis of CXCL9 revealed an extremely high 
value for specificity (96,4%) but a low sensitivity value (45,0%) with an AUC of 68,04% 
(Figure 8) making CXCL9 a decent biomarker for chronic rejection. The NGE values of the 
control group for both chemokines should be higher than NF and CR group, but that 
condition is only verified for CXCL9.   
 The NGE levels of TGF-β1 gene are also in accordance to what was expected due to 
their aptitude to promote interstitial fibrosis, one of the hallmarks of chronic rejection, by 
increasing extracellular matrix proteins and blocking their destruction (166, 167). Szeto et al. 
(168) has already suggested that TGF-β1 gene expression in the urinary sediment may serve 
as an instrument to evaluate the degree of renal injury in chronic kidney diseases. This is 
confirmed by the ROC curve analysis obtained for TGF-β1 where a AUC value of 63,09% can 
be considered acceptable, however, a value of 53,0% (Figure 8) in terms of specificity  can be 
consider inadequate in terms of diagnostic value. 
 The expression of the CXCL10 and CXCL9 genes in both groups suggest an 
involvement of Th1 pathway which culminates in the release of these chemokines.  
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The transcription factor T-bet primer was not available in the Lab, so we had to pick 
the transcription factor GATA3, associated with a Th2 pathway. Normally if one pathway is 
activated the other is downregulated.  
Taking this into account, the NGE values for GATA3 gene were found increased for 
the normal function group with statistical significant differences (Figure 9), implying that the 
development of chronic rejection is more likely associated with a Th1 response rather than 
with Th2, despite CR group having some GATA3 gene amplification. 
 This goes in agreement with the results obtained for the inflammatory chemokines 
and with the some studies stating that Th1-like cytokine and chemokine production, 
triggered by indirect allorecognition, can induce chronic rejection while production of Th2 
cytokines is linked with sheltering from the development of chronic rejection (169).  
The control group displayed higher NGE values than both groups (Figure 9) 
suggesting a prevalence of a Th2 pathway in the cells of urinary sediment of healthy 
individuals. It is important to refer that the IL17 gene had no amplification in neither group, 
suggesting that for this samples the T helper subtype Th17 was not present in the urinary 
sediment. 
 The NGE values obtained for IL4 gene were found increased for the CR Group 
(Figure 9), which was surprising as IL4 is one of the interleukins responsible for promoting a 
Th2 differentiation, it was expected that the expression of this gene would be higher for NF 
group considering the results obtained for GATA3 gene (39).  The ROC curves for GATA3 
and IL4 genes exhibited very low values of specificity (44,3% and 30,2%, respectively) (Figure 
10) exposing a low predictive value for chronic rejection development. 
The NGE values obtained for CD79B and CD19 genes may help explain the apparent 
contradiction of IL4 gene expression values. CD79B gene encodes a subunit of the B cell 
receptor and CD19 encodes a protein found on the surface of B cells, so by evaluating the 
expression of these two genes we are assessing the presence or absence of B cells in the 
urinary sediment of both group of patients (170, 171). 
 The normalized gene expression values of both genes were found higher for CR 
group, with statistically significance differences when compared to NF group (Figure 11), 
indicating a greater presence of B cells during chronic rejection. 
 These results can reinforce the results obtained by Thaunat et al. in explanted 
chronic rejected kidney grafts, claiming the existence of a tertiary lymphoid tissue formed by 
B-cell clusters where B cells can mature. Furthermore, B cells seem to have the ability to 
produce IL4 which might explain the high expression of IL4 in CR group (172).  
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The CD19 gene ROC curve unveiled CD19 has the gene with highest prediction value 
for chronic rejection in this study, with a specificity value of 72,5% and 77,8% for sensitivity 
corresponding to an AUC of 79,15% (Figure 12).  The ROC curve acquired for CD79B gene 
unveiled a low sensitivity value (50,0%) and a decent specificity value (72,9%) with an AUC of 
59,9% (Figure 12) indicating a poor value of diagnostic for chronic rejection. 
 Finally, the last 3 genes whose expression was evaluated in the urinary sediment were 
IL10, TNF3 and FOXP3. IL10 is an anti-inflammatory cytokine and normally is produced by 
regulatory T cells (173). FOXP3 is a transcription factor necessary for the development and 
function of regulatory T cells (110). FOXP3 and IL10 are often associated with allograft 
acceptance as regulatory T cells play a crucial part in the development of tolerance (55).  
TNF3 encodes a part of  the all TNFα that plays a crucial role in inflammation 
processes by inducing a variety of cellular responses, which include cell death, survival, 
differentiation, proliferation and migration(174).  
Inflammatory processes are part of chronic rejection disease so TNF3 is an important 
gene to evaluate. The NGE values of TNF3 confirmed this propensity for allograft 
inflammation in chronic rejection as they were significantly increased in CR group (Figure 
13).  
The NGE values for FOXP3 genes were, as expected, superior for NF group (Figure 
13), as explained above there are numerous studies associating FOXP3 expression with 
tolerance and extended graft survival, however no significant differences were achieved for 
this gene (74, 175).  
Interestingly, the  expression of the same gene in a previous study done in our lab 
was also found increased for NF group with statistical significance, but the analysis was 
performed in peripheral blood samples indicating that peripheral blood analysis would be the 
best fit for FOXP3 gene expression analysis (data not published).   
The NGE values for IL10 gene were unexpectedly increased in the CR group with 
statistical significance (Figure 13). A possible explanation for this result is the low number of 
samples that had amplification for this gene which can lead to inaccurate results. Moreover, 
through the years some studies have reported the role of IL10 in B cell activation and 
proliferation, so the high expression of IL10 gene can be linked to the greater presence of B 
cells in the urinary sediment of patients diagnosed with chronic rejection (176-178).  
IL10 gene expression was also evaluated in the peripheral blood in a prior study and 
the NGE values were also found higher for CR group with statistical significant differences 
between NF and CR group (data not published).  
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The ROC curve analyses for IL10 gene showed an AUC of 76,23% with specificity  
and sensitivity values of 82.4% and 66,7% (Figure 14). These are decent predictive values, 
however, due to the low number of samples that had amplification IL10 cannot be chosen, in 
this study, as a suitable biomarker, for chronic rejection.  
At last, the TNF3 gene exhibited an AUC of 72,25% with a specificity value of 76,2% 
and a sensitivity value of 66,0% (Figure 14) which are respectable values for diagnosis of 
chronic rejection. CD19, TNF3 and CXCL10 genes showed the greatest potential as a 
biomarker for chronic rejection. 
 In my opinion, the best way to integrate the qRT-PCR as a standard diagnostic 
procedure for chronic rejection in renal transplant patients, would be to perform the gene 
expression evaluation in both urine and blood samples, as it becomes clear from this study 
and previous works that changes in the expression of certain genes are detectable in the 
urine ( CD19, TNF3 and CXCL10, for example) and others are only visible in the blood 
(FOXP3). By doing both analysis, the results obtained would be more reliable and could lead 
to early and accurate diagnosis of this condition that still is the major problem in 
transplantation.
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This study intended to perform a complete evaluation of the urine of renal transplant 
patients, in order to find potential biomarkers of chronic rejection, that may allow transplant 
monitoring without recourse to invasive techniques but, above all, it was meant to 
contribute to increase the knowledge of the mechanisms behind chronic rejection as this 
disease still is a major concern in transplantation. 
 Regardless of the minimum criteria applied for sample selection, the two groups 
(patients with a stable/normal graft function and patients diagnosed with chronic rejection) 
exhibited a decent homogeneity in their clinical and demographic features with the main 
difference being the higher percentage of previous acute rejection episodes in the chronic 
rejection group reinforcing the significance of acute rejection in the development of chronic 
rejection. 
 In the present study, the relationship between the presence of anti-HLA antibodies 
and the gradual decline of allograft function was not totally verified. Indeed for anti-HLA 
Class I antibodies the percentage of patients was higher for NF group and even though the 
percentage of patients with detectable anti-HLA Class II antibodies was higher in CR group 
the differences were not significant. 
 The relationship established, by various studies, between the number of HLA 
mismatches and the detection anti-HLA antibodies in the serum could only been verified for 
anti-HLA Class I antibodies in NF group where the number of patients with anti-HLA 
antibodies was higher for 2 or more HLA mismatches. 
 One of the most relevant points in this study was the development of an antibody 
screening method in the urine of renal transplant patients. This method allowed the 
detection of anti-HLA antibodies in renal transplant patients who had not showed any 
evidence of having anti-HLA antibodies in circulation, particularly, in CR group where more 
than half the patients presented anti-HLA Class I antibodies in urine. This increased 
percentage reinforces the relevance of these antibodies in the development of chronic 
rejection by inducing inflammatory responses and by their capacity to stimulate proliferation 
of endothelial cells.  
 This method still needs technical validation but the results obtained showed that 
urine can really be crucial to assess all features involved in graft dysfunction. Furthermore, 
the follow up of the patients with a normal graft function that had anti-HLA antibodies could 
validate this method as diagnostic tool for chronic rejection in renal transplant, if these 
patients develop this condition. If so, the antibody screening method could be implemented 
as a standard procedure and together with the screening in the serum, the information 
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generated would be more precise and could lead to an early diagnose of chronic rejection or 
at least would help identify the patients more susceptible to develop this condition. 
 In terms of gene expression in the urinary sediment of renal transplant patients, the 
normalized gene expression values for the inflammatory chemokines, CXCL10 and CXCL9, 
were higher for CR group verifying the role of inflammation in chronic rejection 
development and showing that both can be potentially decent biomarkers for rejection, 
specially CXCL10. 
The higher NGE values for TGF-β1 gene for CR group tend to show the involvement 
of this molecule in loss of graft function as it is able to promote the establishment of 
interstitial fibrosis, a hallmark of chronic rejection. 
 The increased NGE values for GATA3 gene found in NF group, suggest that Th2 
pathway may be involved in the development of graft tolerance. On the other hand, the 
lower expression of GATA3 gene in chronic rejection group indicates a preference of Th1  
differentiation pathway in the development of the disease. In future works, it would be 
important to evaluate the expression of the transcription factor T-bet and IL12 in order to 
confirm that Th1 differentiation is more active in the urinary sediment of renal transplant 
patients diagnosed with chronic rejection.  
 Concerning the NGE values obtained for CD19, CD79 and IL4 genes, the increased 
expression in chronic rejection patients indicates a greater presence of B cells in the urinary 
sediment of these patients. This goes in agreement with the studies performed by Thaunat et 
al. that report the existence of B cells clusters, similarly to a lymphoid tissue, capable of 
harbouring B cells maturation that may have a crucial role in the development of chronic 
rejection.  
The higher presence of B cells in the urinary sediment of chronic rejection patients 
can also support the increased frequency of anti-HLA antibodies found in the urine of these 
patients as B cells are the major precursors of alloantibodies.  Moreover, Thaunat et al also 
stated that the maturation of B cells in these clusters could be impeded by blocking the 
expression of certain genes, so these genes may constitute potential drug targets for 
treatment of chronic rejection or at least, for causing a delay in the development of this 
condition, increasing the survival rates of renal transplant patients. 
 Regarding the NGE values of the transcription factor FOXP3, characteristic of 
regulatory T cells, the increased levels for the normal function group confirms the 
involvement of these cells in induction of graft tolerance as these values were found.  
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 Finally, TNF3 gene expression levels were higher for CR group proving once again 
that allograft inflammation is a characteristic of chronic rejection development. The IL10 
gene expression values were also increased for CR group, but for this gene very few samples 
amplified so the results might be misleading. 
 The analysis of the receiving operating characteristic (ROC) curves revealed CD19, 
CXCL10 and TNF3 as the genes with the highest significant predicting value for chronic 
rejection in the sample studied, so in future works this should be taking into account. 
 The ideal control group, for this type of study, should be composed of patients who 
were submitted to a renal transplant but do not require immunosuppressive agents to 
survive in order to identify the gene expression values that result from renal transplant 
alone. However it is almost impossible to get blood and urine samples from these patients 
so to overcome this barrier, In future works more restricted criteria should be applied in 
sample selection to get even more homogeneity in the groups.  
Another important point is the identification by “Single Antigen” assays of the anti-
HLA antibodies found in the urine and serum samples, whose results were not presented 
here due to the lack of sufficient reagents to proceed to the analysis of all the samples. It 
would be interesting to know if the detected anti-HLA antibodies were donor-specific or 
not. Also in the future, the study design should be reconsidered, for example, the urine and 
blood samples should be taken every 3 months for a period of 3 years to evaluate the 
differences of gene expression and antibody screening over time 
In conclusion, the results obtained in the antibody screening and gene expression 
analysis of the urine of renal transplant patients prove that the urine can be an important 
biological material to examine and can give vital information to assess the clinical condition 
of renal transplant patients.  
However, the analysis of peripheral blood samples cannot be excluded or discarded. 
In fact, only the conjugation of both analyses provides a complete evaluation of the allograft 
as most of the clinical and histopathological manifestations of chronic rejection happening 
locally are also reflected in the surrounding regions.  
Future works, may include flow cytometry analysis of the urine of these patients 
which  should  add vital information like, the number of cells present in each sample and 
even more importantly, could help identify the type of cells in the urinary sediment which 
would have a significant impact in the interpretation of the other results. 
It is important to underline that the contribution of this work is very small, given the 
complexity of the mechanisms wrapped in the development of chronic rejection.
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